Fusion glycoprotein F0

Fusion glycoprotein F0

Fusion glycoprotein F0 詳細

Molecule Name
Respiratory syncytial virus F protein
分子の別称
Fusion glycoprotein F0
Drug Development Progress
治験薬の数5
市販薬剤の数3
研究&開発段階Approved
ターゲットの別称
Protein F,F,Fusion glycoprotein F0
バックグランド
The two surface glycoproteins of the mumps virus are the hemagglutinin-neuraminidase (HN) and Fusion proteins. These glycoproteins are essential for viral entry to host cells, and the spread of newly formed virions. The mumps fusion protein (F) is a 538-amino acid, class one fusion surface glycoprotein. It is responsible for the membrane fusion of virus and host cell. The un-cleaved protein has three hydrophobic regions: an amino-terminal signal peptide, an amino terminal region of F1 and the carboxyl-terminal membrane domain. This protein starts as a precursor molecule (F0), and is then cleaved into the active protein by the recognition of a R-X-L/R-R motif by a host endoprotease (furin). The F protein contains two disulfide-linked polypeptides (F1 and F2).

Fusion glycoprotein F0 製品リスト

Species
  • Mumps virus(1)
Tag
  • His Tag & Avi Tag(1)
Host
  • HEK293(1)
Conjugate
  • Biotin-labeled(1)
Grade
  • RUO(1)
Low Endotoxin
  • No(1)
MoleculeCat. No.Product Name種HostStructurePurityActivitySize&Price
Fusion glycoprotein F0
Avitag
RSF-M82E3
Biotinylated Mumps virus (strain Miyahara vaccine) (MuV) Fusion glycoprotein F0 Protein, His,Avitag™
Mumps virus
HEK293
SDS-PAGE

$1520.00

200ug
You Have Viewed 1-1 Of 1 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
CPI-RSV-F VaccineBLB-201Phase 2 ClinicalBlue Lake Biotechnology Inc
Respiratory Syncytial Virus Infections
詳細
RSV vaccine (Vaxart)Phase 1 ClinicalVaxart Biosciences Inc
Respiratory Syncytial Virus Infections
詳細
GR-2102GR2102; GR-2102Phase 1 ClinicalChongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd
Respiratory Syncytial Virus Infections
詳細
Palivizumab biosimilar (mAbxience)MB-05Phase 1 ClinicalMabxience Sa
詳細
RSM-01Phase 1 ClinicalBill & Melinda Gates Medical Research Institute
Respiratory Syncytial Virus Infections
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
NirsevimabAnti-RSV-mAb-D25; SP-0232; MEDI-8897; Anti-RSV MAb-YTEApprovedAimm Therapeutics, MedImmune Inc, SanofiBeyfortus, 乐唯初EURespiratory Syncytial Virus InfectionsSanofi Winthrop Industrie SA2022-10-31
Lower Respiratory Tract Infections; Respiratory Syncytial Virus Infections
詳細
PalivizumabABT-315; MEDI-493ApprovedAbbvie Inc, Medimmune LlcSynagisUnited StatesRespiratory Syncytial Virus InfectionsSwedish Orphan Biovitrum Ab (Publ)1998-06-19
Bronchiolitis; Bronchopulmonary Dysplasia; Heart Defects, Congenital; Infant, Premature, Diseases; Premature Birth; Respiratory Syncytial Virus Infections
詳細
Respiratory syncytial virus immune globulinRSV-IGIVApprovedMedimmuneRespiGamUnited StatesRespiratory Syncytial Virus Infectionsnull1996-01-01
Respiratory Syncytial Virus Infections
詳細
Customer Reviews